HTA Barriers for Conditional Approval Drugs
Author
Abstract
Suggested Citation
DOI: 10.1007/s40273-023-01248-9
Download full text from publisher
As the access to this document is restricted, you may want to search for a different version of it.
References listed on IDEAS
- Patricia M. Danzon & Y. Richard Wang & Liang Wang, 2005.
"The impact of price regulation on the launch delay of new drugs—evidence from twenty‐five major markets in the 1990s,"
Health Economics, John Wiley & Sons, Ltd., vol. 14(3), pages 269-292, March.
- Patricia M. Danzon & Y. Richard Wang & Liang Wang, 2003. "The Impact of Price Regulation on the Launch Delay of New Drugs - Evidence from Twenty-Five Major Markets in the 1990s," NBER Working Papers 9874, National Bureau of Economic Research, Inc.
- Nicod, Elena & Maynou, Laia & Visintin, Erica & Cairns, John, 2020. "Why do health technology assessment drug reimbursement recommendations differ between countries? A parallel convergent mixed methods study," Health Economics, Policy and Law, Cambridge University Press, vol. 15(3), pages 386-402, July.
- Maynou, Laia & Cairns, John, 2019. "What is driving HTA decision-making? Evidence from cancer drug reimbursement decisions from 6 European countries," Health Policy, Elsevier, vol. 123(2), pages 130-139.
- Lundkvist, Jonas & Jonsson, Bengt & Rehnberg, Clas, 2006. "The costs and benefits of regulations for reimbursement of new drugs," Health Policy, Elsevier, vol. 79(2-3), pages 337-344, December.
Most related items
These are the items that most often cite the same works as this one and are cited by the same works as this one.- Anderson, Michael & Drummond, Michael & Taylor, David & McGuire, Alistair & Carter, Paul & Mossialos, Elias, 2022. "Promoting innovation while controlling cost: The UK's approach to health technology assessment," Health Policy, Elsevier, vol. 126(3), pages 224-233.
- Vincenzo Atella & Jay Bhattacharya & Lorenzo Carbonari, 2008.
"Pharmaceutical Industry, Drug Quality and Regulation: Evidence from US and Italy,"
NBER Working Papers
14567, National Bureau of Economic Research, Inc.
- Vincenzo Atella & Jay Bhattacharya & Lorenzo Carbonari, 2008. "Pharmaceutical industry, drug quality and regulation. Evidence from US and Italy," CEIS Research Paper 138, Tor Vergata University, CEIS, revised 16 Dec 2008.
- Nebibe Varol & Joan Costa-i-Font & Alistair McGuire, 2011. "Explaining Early Adoption on New Medicines: Regulation, Innovation and Scale," CESifo Working Paper Series 3459, CESifo.
- Håkonsen, Helle & Horn, Anne Marie & Toverud, Else-Lydia, 2009. "Price control as a strategy for pharmaceutical cost containment--What has been achieved in Norway in the period 1994-2004?," Health Policy, Elsevier, vol. 90(2-3), pages 277-285, May.
- Patricia M. Danzon & Eric L. Keuffel, 2014. "Regulation of the Pharmaceutical-Biotechnology Industry," NBER Chapters, in: Economic Regulation and Its Reform: What Have We Learned?, pages 407-484, National Bureau of Economic Research, Inc.
- Pierre Dubois & Morten Sæthre, 2020.
"On the Effect of Parallel Trade on Manufacturers' and Retailers' Profits in the Pharmaceutical Sector,"
Econometrica, Econometric Society, vol. 88(6), pages 2503-2545, November.
- Dubois, Pierre & Sæthre, Morten, 2017. "On the Effect of Parallel Trade on Manufacturers’ and Retailers’ Profits in the Pharmaceutical Sector," Discussion Paper Series in Economics 3/2018, Norwegian School of Economics, Department of Economics.
- Pierre Dubois & Morten Sæthre, 2020. "On the Effect of Parallel Trade on Manufacturers’ and Retailers’ Profits in the Pharmaceutical Sector," Post-Print hal-03176406, HAL.
- Dubois, Pierre & Saethre, Morten, 2018. "On the Effect of Parallel Trade on Manufacturers’ and Retailers’ Profits in the Pharmaceutical Sector," TSE Working Papers 18-883, Toulouse School of Economics (TSE), revised Mar 2020.
- Dubois, Pierre & Saethre, Morten, 2018. "On the Effect of Parallel Trade on Manufacturers' and Retailers' Profits in the Pharmaceutical Sector," CEPR Discussion Papers 12649, C.E.P.R. Discussion Papers.
- Begoña Garcia Mariñoso & Izabela Jelovac & Pau Olivella, 2011.
"External referencing and pharmaceutical price negotiation,"
Health Economics, John Wiley & Sons, Ltd., vol. 20(6), pages 737-756, June.
- Begoña Garcia Mariñoso & Izabela Jelovac & Pau Olivella, 2008. "External referencing and pharmaceutical price negotiation," Working Papers 0815, Groupe d'Analyse et de Théorie Economique Lyon St-Étienne (GATE Lyon St-Étienne), Université de Lyon.
- Begoña Garcia Mariñoso & Izabela Jelovac & Pau Olivella, 2011. "External referencing and pharmaceutical price negotiation," Post-Print halshs-00303682, HAL.
- Begoña Garcia Mariñoso & Izabela Jelovac & Pau Olivella, 2010. "External referencing and pharmaceutical price negotiation," Post-Print halshs-00955856, HAL.
- Kurt Brekke & Dag Dalen & Tor Holmås, 2014.
"Diffusion of pharmaceuticals: cross-country evidence of anti-TNF drugs,"
The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(9), pages 937-951, December.
- Brekke, Kurt R. & Dalen, Dag Morten & Holmås, Tor Helge, 2013. "Diffusion of Pharmaceuticals: Cross-Country Evidence of Anti-TNF drugs," Discussion Paper Series in Economics 7/2013, Norwegian School of Economics, Department of Economics.
- Chatterjee, Chirantan & Kubo, Kensuke & Pingali, Viswanath, 2015. "The consumer welfare implications of governmental policies and firm strategy in markets for medicines," Journal of Health Economics, Elsevier, vol. 44(C), pages 255-273.
- Senra de Morais, Rafael Pinho, 2017. "Compulsory licensing of pharmaceuticals by the developing south," Economics Letters, Elsevier, vol. 161(C), pages 74-77.
- Verniers, Isabel & Stremersch, Stefan & Croux, Christophe, 2011. "The global entry of new pharmaceuticals: A joint investigation of launch window and price," International Journal of Research in Marketing, Elsevier, vol. 28(4), pages 295-308.
- Simone Ghislandi & Michael Kuhn, 2016.
"Asymmetric information in the regulation of the access to markets,"
Department of Economics Working Papers
wuwp219, Vienna University of Economics and Business, Department of Economics.
- Ghislandi, Simone & Kuhn, Michael, 2016. "Asymmetric information in the regulation of the access to markets," Department of Economics Working Paper Series 219, WU Vienna University of Economics and Business.
- Frank R. LICHTENBERG, 2018.
"The Impact of New Drug Launch on Life-Years Lost in 2015 from 19 Types of Cancer in 36 Countries,"
JODE - Journal of Demographic Economics, Cambridge University Press, vol. 84(3), pages 309-354, September.
- Lichtenberg, Frank R., 2018. "The Impact Of New Drug Launches On Life-Years Lost In 2015 From 19 Types Of Cancer In 36 Countries," Journal of Demographic Economics, Cambridge University Press, vol. 84(3), pages 309-354, September.
- Frank R. Lichtenberg, 2018. "The Impact of New Drug Launches on Life-Years Lost in 2015 from 19 Types of Cancer in 36 Countries," NBER Working Papers 24536, National Bureau of Economic Research, Inc.
- Frank R. Lichtenberg, 2018. "The Impact of New Drug Launches on Life-Years Lost in 2015 from 19 Types of Cancer in 36 Countries," Working Papers id:12757, eSocialSciences.
- Nicolas Houy & Izabela Jelovac, 2014.
"Drug approval decision times, international reference pricing and strategic launches of new drugs,"
Working Papers
halshs-01072741, HAL.
- Izabela Jelovac, 2015. "Drug approval decision times, international reference pricing and strategic launches of new drugs," Post-Print halshs-01178631, HAL.
- Nicolas Houy & Izabela Jelovac, 2014. "Drug approval decision times, international reference pricing and strategic launches of new drugs," Working Papers 1425, Groupe d'Analyse et de Théorie Economique Lyon St-Étienne (GATE Lyon St-Étienne), Université de Lyon.
- Izabela Jelovac, 2015. "Drug approval decision times, international reference pricing and strategic launches of new drugs," Post-Print halshs-01178636, HAL.
- Izabela Jelovac & Nicolas Houy, 2015. "Drug approval decision times, international reference pricing and strategic launches of new drugs," Post-Print halshs-01261578, HAL.
- Izabela Jelovac, 2014. "Drug approval decision times, international reference pricing and strategic launches of new drugs," Post-Print halshs-01138229, HAL.
- Izabela Jelovac, 2015. "Drug approval decision times, international reference pricing and strategic launches of new drugs," Post-Print halshs-01178630, HAL.
- Izabela Jelovac & Nicolas Houy, 2017. "Drug approval decision times, international reference pricing and strategic launches of new drugs," Post-Print halshs-01657274, HAL.
- Kai Li & Cheryl Long & Wei Wan, 2019. "Public Interest or Regulatory Capture: Theory and Evidence from China’s Airfare Deregulation," Working Papers 2019-01, Wang Yanan Institute for Studies in Economics (WISE), Xiamen University.
- Yiyin Cao & Haofei Li & Ling Jie Cheng & Madeleine T. King & Georg Kemmler & David Cella & Hongjuan Yu & Weidong Huang & Nan Luo, 2024. "A comparison of measurement properties between EORTC QLU-C10D and FACT-8D in patients with hematological malignances," Health Economics Review, Springer, vol. 14(1), pages 1-10, December.
- Verdiana Giannetti & Gaia Rubera, 2020. "Innovation for and from emerging countries: a closer look at the antecedents of trickle-down and reverse innovation," Journal of the Academy of Marketing Science, Springer, vol. 48(5), pages 987-1008, September.
- Eric W. Bond & Kamal Saggi, 2023.
"Bargaining over Entry with a Compulsory License Deadline: Price Spillovers and Surplus Expansion,"
World Scientific Book Chapters, in: Kamal Saggi (ed.), Technology Transfer, Foreign Direct Investment, and the Protection of Intellectual Property in the Global Economy, chapter 20, pages 449-480,
World Scientific Publishing Co. Pte. Ltd..
- Eric W. Bond & Kamal Saggi, 2017. "Bargaining over Entry with a Compulsory License Deadline: Price Spillovers and Surplus Expansion," American Economic Journal: Microeconomics, American Economic Association, vol. 9(1), pages 31-62, February.
- Eric W Bond & Kamal Saggi, 2016. "Bargaining over entry with a compulsory license deadline: Price spillovers and surplus expansion," Vanderbilt University Department of Economics Working Papers 16-00009, Vanderbilt University Department of Economics.
- Frank R. Lichtenberg, 2019. "How Many Life-Years Have New Drugs Saved? A 3-Way Fixed-Effects Analysis of 66 Diseases in 27 Countries, 2000-2013," NBER Working Papers 25483, National Bureau of Economic Research, Inc.
- Y. Wang, 2006. "Price competition in the chinese pharmaceutical market," International Journal of Health Economics and Management, Springer, vol. 6(2), pages 119-129, June.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharme:v:41:y:2023:i:5:d:10.1007_s40273-023-01248-9. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .
Please note that corrections may take a couple of weeks to filter through the various RePEc services.